VBR

Douglas Landin Joins The Exclusive Haute Residence Real Estate Network

Retrieved on: 
Jeudi, avril 11, 2024
Colorado Rockies, VBR, Golf, Knowledge, Network, Real estate

VAIL VALLEY, Colo., April 11, 2024 /PRNewswire-PRWeb/ -- One of the most popular residential real estate brokers in the Vail Valley, known for his professional style and extensive knowledge of the local market, Doug's connection to Vail dates back to 1975 when he became a ski instructor for Vail Resorts for 23 years. Based in Lionshead, Doug has been a real estate broker exceeding 29 years, working with buyers and sellers throughout the Vail Valley. Sales expanding more than 700 properties, his top achievements include holding the title of 2022 Real Trends America's Best, Top 1.5% Brokers in the country, and 2015 VBR Realtor® of the Year. Doug was honored to be named Chairman of the Vail Board of Realtors and Vice President for the Colorado Association of Realtors Mountain District. He was the recipient of the Jo Brown Community Service Award for his involvement in business and community events; an additional accolade is that he founded the Vail Automotive Classic (VailAutomotiveClassic.com), the premier automotive gathering in the Colorado Rockies and a notable charity fundraiser. Married with two daughters, Doug lives in Eagle Ranch and is an avid skier. He enjoys cycling, golf, and everything outdoors. He takes great pleasure in introducing new "locals" to the expansive lifestyle opportunities throughout the Vail Valley.

Key Points: 
  • Acclaimed real estate agent Douglas Landin accepts the invitation to Haute Residence's invite-only Network.
  • Based in Lionshead, Doug has been a real estate broker exceeding 29 years, working with buyers and sellers throughout the Vail Valley.
  • Based in Lionshead, Doug has been a real estate broker for over 29 years.
  • Visit Douglas Landin's Haute Residence Profile: https://www.hauteresidence.com/member/douglas-landin/

ChoiceSpine LLC Announces Changes in Leadership Roles

Retrieved on: 
Jeudi, janvier 18, 2024
Health Technology, Health, Surgery, Medical Devices, Clemson University, Senior, Family, Spinal fusion, VBR, Ruby, International business, Biological engineering, PYA, Katz Broadcasting, Spine, Mechanical, MBA, Investment, 3D, FDA, Doctor of Philosophy, East Tennessee State University, Mechanical engineering, Growth, Management

ChoiceSpine LLC, a medical device company in Knoxville, Tennessee, and privately held by Altus Capital Partners, announces that Marty Altshuler and Rick Henson, founders and Co-Presidents of ChoiceSpine, transitioned to Executive Advisor roles following 18 years of leading the company.

Key Points: 
  • ChoiceSpine LLC, a medical device company in Knoxville, Tennessee, and privately held by Altus Capital Partners, announces that Marty Altshuler and Rick Henson, founders and Co-Presidents of ChoiceSpine, transitioned to Executive Advisor roles following 18 years of leading the company.
  • Conjointly, effective January 01, 2024, the Board of Directors for ChoiceSpine, LLC selected Stephen Ainsworth, Executive Vice President of Strategy and Technology, and Andy Broyles, Chief Financial Officer, to succeed Mr. Altshuler and Mr. Henson as Co-Presidents of ChoiceSpine.
  • Mr. Altshuler and Mr. Henson will remain with ChoiceSpine, serving on the Board of Directors and as advisors to the Executive Team.
  • This strategic move is poised to enhance the company's innovative edge and continued growth in the spine market.

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

Retrieved on: 
Vendredi, novembre 10, 2023
Hepatology, VBR, Interferon, Viral, SAN, Hepatitis B virus, AASLD, Liver, Biotechnology, Patient, HBV, ISG, Assembly, HCV, Doctor of Philosophy, Poster, Pharmaceutical industry, Vaccine, Boston

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • “Additionally, the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 provide further insights that may inform future studies for the HBV and liver disease scientific community."
  • In addition, oral administration to preclinical species resulted in ISG induction in the liver and peripheral blood mononuclear cells (PBMCs).
  • Assembly Bio intends to make the presentations available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com.

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Retrieved on: 
Mercredi, octobre 11, 2023
CHB, Neoplasm, Virology, HBsAg, Hepatology, Viral, PD-L1, Therapy, American Association for Cancer Research, Liver, AASLD, RNA interference, Hepatitis B, Database, Single-nucleotide polymorphism, Repeat, HBV, Publication, Safety, VBR, HCC, Patient, Pharmaceutical industry, Vaccine, Silviculture

WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data from the Company’s lead HBV focused asset, imdusiran (AB-729), an RNAi therapeutic, and preclinical data from its oral PD-L1 inhibitor program, will be highlighted in oral and poster presentations, including a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.

Key Points: 
  • Data Summary: Treatment with oral small-molecule PD-L1 inhibitors possessing liver-tropic pharmacokinetic profiles was associated with increased efficacy and tumor clearance in a novel humanized orthotopic HCC mouse model.
  • These data suggest that development of small-molecule PD-L1 inhibitors with biodistribution to the liver may provide benefit in the treatment of HCC.
  • Available data indicate that adding VBR to AB-729+NrtI does not result in significantly greater on- or post-treatment improvements in markers of active HBV infection vs AB-729+NrtI.
  • The poster presentations will available on Arbutus’ website on November 10, 2023 and can be accessed through the Publications section at https://www.arbutusbio.com/publications/ .

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Retrieved on: 
Mercredi, octobre 11, 2023
Assembly, Doctor of Philosophy, Hepatology, Viral, American Association for the Study of Liver Diseases, AASLD, Biotechnology, Liver, HBV, Patient, VBR, Poster, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • At the meeting, one poster presentation will share new preclinical data from the Company’s interferon-α receptor (IFNAR) agonist program in chronic hepatitis B virus (HBV), currently in lead optimization.
  • Additionally, an oral presentation will highlight data from the Phase 2 study of first-generation core inhibitor vebicorvir (VBR) in combination with nucleos(t)ide reverse transcriptase inhibitor (Nrtl) and Arbutus Biopharma’s AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
  • “We look forward to presenting data at this year’s AASLD, The Liver Meeting®, featuring the exciting progress of our preclinical IFNAR agonist program and its potential to engage the interferon-α pathway with improved tolerability through an oral, liver-focused approach,” said William Delaney, PhD, chief scientific officer of Assembly Bio.
  • “Additionally, we’re pleased to share further insights from the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 with the HBV and liver disease scientific community."

Alpha and Omega Semiconductor Announces Ultra-Low Reverse Working Voltage TVS Diode for USB4 and Thunderbolt 4 ESD Protection

Retrieved on: 
Mercredi, septembre 20, 2023
Technology, Hardware, Electronic Design Automation, Semiconductor, Failure, Thunderbolt (interface), USB, IC, Multimedia, VBR, ICS, HDMI, SMD, AOS, FOM, USB4, TVS, ESD, Electronics, Printed circuit board, Alpha, Thunderbolt

Designed to deliver extremely low capacitance and fast response time, the AOZ8S207BLS-01 TVS diode offers superior high-speed data line protection based on AOS’ advanced Ultra-Low Breakdown Voltage (VBR) TVS platform and innovative packaging.

Key Points: 
  • Designed to deliver extremely low capacitance and fast response time, the AOZ8S207BLS-01 TVS diode offers superior high-speed data line protection based on AOS’ advanced Ultra-Low Breakdown Voltage (VBR) TVS platform and innovative packaging.
  • These features, along with the TVS diode’s 0.15pf capacitance, make it ideal for USB4 and Thunderbolt 4 electrostatic discharge (ESD) protection.
  • View the full release here: https://www.businesswire.com/news/home/20230920833080/en/
    Ultra-Low Reverse Working Voltage TVS Diode for USB4 and Thunderbolt 4 ESD Protection (Graphic: Business Wire)
    Low breakdown voltage is essential for ESD protection devices, especially when protecting ICs manufactured with the finest process.
  • This feature-rich TVS diode makes an excellent solution for high-speed data line protection,” said Charles Chen, Marketing Director at AOS.

Simplify Healthcare Is Positioned in the Leaders Category in the 2023 IDC MarketScape for U.S. Health Plan Product/Plan Benefit Configuration Solutions

Retrieved on: 
Mercredi, août 9, 2023
Technology, Payments, Hospitals, Security, Health Technology, Software, Practice Management, Health, Data Management, Cloud, IDC, CMS, Payment, Marketing, Health care, VBR, Organization, Medicare, DOI, ASO, TPA, Environment, Health insurance, Medicaid

Simplify Healthcare , a leading healthcare Payer technology company, announced that it has been positioned in the Leaders Category in the 2023 IDC MarketScape for U.S. health plan product/plan benefit configuration solutions (doc #US50826823, June 2023).

Key Points: 
  • Simplify Healthcare , a leading healthcare Payer technology company, announced that it has been positioned in the Leaders Category in the 2023 IDC MarketScape for U.S. health plan product/plan benefit configuration solutions (doc #US50826823, June 2023).
  • The vendors included in this study supply standalone product/plan configuration solutions to Payer and TPA organizations, whether supporting commercial or governmental (Medicare and Medicaid) plans.
  • This IDC MarketScape study provides an evaluation of five vendors that provide Payer solutions for product/plan configuration.
  • “We believe being named to the Leaders Category in the IDC MarketScape has recognized the value we provide to Payer, TPA, and ASO operations.

Infortrend's EonStor GS G3 Now Supports the New Veeam Data Platform for Immutable Backup to Mitigate Ransomware Attacks

Retrieved on: 
Mardi, août 8, 2023
Daou Technology Inc., NAS, V12, Veeam, VBR, TWSE, U.2, SSD, RpoS, Monolithic kernel, Computer data storage

This provides businesses with an increasingly popular immutable backup for protecting data and ensuring its fast recoverability in case of ransomware attacks.

Key Points: 
  • This provides businesses with an increasingly popular immutable backup for protecting data and ensuring its fast recoverability in case of ransomware attacks.
  • A Veeam survey of 4,200 enterprises showed that over 85% experienced ransomware attack in 2022, and 79% have a data protection gap.
  • However, with Infortrend EonStor GS G3 and VBR V12, businesses now have an immutable backup solution for faster and guaranteed data recovery compared to traditional tape backup.
  • Furthermore, GS G3 supports S3-compatible object storage for an immutable Veeam backup repository, which prevents any unauthorized modifications and protects against malicious acts.

Infortrend's EonStor GS G3 Now Supports the New Veeam Data Platform for Immutable Backup to Mitigate Ransomware Attacks

Retrieved on: 
Mardi, août 8, 2023
Daou Technology Inc., NAS, V12, Veeam, VBR, TWSE, U.2, SSD, RpoS, Monolithic kernel, Computer data storage

This provides businesses with an increasingly popular immutable backup for protecting data and ensuring its fast recoverability in case of ransomware attacks.

Key Points: 
  • This provides businesses with an increasingly popular immutable backup for protecting data and ensuring its fast recoverability in case of ransomware attacks.
  • A Veeam survey of 4,200 enterprises showed that over 85% experienced ransomware attack in 2022, and 79% have a data protection gap.
  • However, with Infortrend EonStor GS G3 and VBR V12, businesses now have an immutable backup solution for faster and guaranteed data recovery compared to traditional tape backup.
  • Furthermore, GS G3 supports S3-compatible object storage for an immutable Veeam backup repository, which prevents any unauthorized modifications and protects against malicious acts.

Quantum Integrates Comprehensive Enterprise Backup and Data Protection Portfolio with Latest Veeam Data Platform

Retrieved on: 
Mercredi, juin 28, 2023
V12, RPO, VDMS, VBR, DirectX plugin, Veeam Backup & Replication, SAN, Quantum, Environment, Computer data storage, Veeam

SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Quantum, the leader in solutions for unstructured data, today announced the qualification of its comprehensive enterprise backup storage portfolio with the new Veeam® Data Platform, which includes Veeam Backup & Replication™ (VBR) V12. With this announcement, Quantum now offers a broad portfolio of Veeam Ready storage solutions, giving customers the most choice and security for backing up and protecting data, including:

Key Points: 
  • Broad set of Veeam Ready solutions deliver multi-layered data protection, strengthen cybersecurity, provide rapid recovery, immutability, and offline protection against ransomware
    SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Quantum, the leader in solutions for unstructured data, today announced the qualification of its comprehensive enterprise backup storage portfolio with the new Veeam® Data Platform , which includes Veeam Backup & Replication™ (VBR) V12 .
  • "The new Veeam Data Platform delivers more advanced data security, recovery, and hybrid cloud capabilities than ever," says Andreas Neufert, vice president of product management, alliances, for Veeam.
  • "Quantum's enterprise backup solutions leverage the Veeam Data Platform, which includes Veeam Backup & Replication V12, providing best-in-class secure backup and recovery to keep businesses running.
  • To learn more about the new Veeam Data Platform and Quantum solutions, visit www.quantum.com/veeam .